Breakdown | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 20.18B | 19.37B | 18.87B | 20.25B | 17.12B |
Gross Profit | 9.13B | 8.17B | 8.48B | 9.43B | 7.58B |
EBITDA | 4.82B | 4.28B | 4.29B | 4.25B | 2.97B |
Net Income | 1.71B | 1.48B | 1.78B | 2.09B | 874.00M |
Balance Sheet | |||||
Total Assets | 57.29B | 52.78B | 52.93B | 53.87B | 54.01B |
Cash, Cash Equivalents and Short-Term Investments | 2.16B | 1.42B | 1.01B | 2.29B | 2.85B |
Total Debt | 20.11B | 15.88B | 16.07B | 17.61B | 17.93B |
Total Liabilities | 31.40B | 26.98B | 27.63B | 30.19B | 30.24B |
Stockholders Equity | 25.89B | 25.80B | 25.30B | 23.68B | 23.77B |
Cash Flow | |||||
Free Cash Flow | 3.07B | 2.12B | 1.66B | 3.42B | 2.73B |
Operating Cash Flow | 3.80B | 2.99B | 2.63B | 4.65B | 3.54B |
Investing Cash Flow | -5.51B | -716.00M | -3.23B | -1.88B | -1.23B |
Financing Cash Flow | 2.09B | -1.96B | -591.00M | -3.31B | 22.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
83 Outperform | $40.08B | 30.69 | 25.81% | 0.78% | 9.54% | 37.23% | |
78 Outperform | $16.33B | 35.70 | 17.72% | 0.30% | 2.89% | -5.50% | |
73 Outperform | $14.64B | 35.59 | 5.15% | ― | 6.88% | 21.11% | |
70 Outperform | $52.33B | 34.84 | 5.97% | 2.22% | 5.84% | 15.12% | |
70 Outperform | $14.70B | 27.85 | 11.77% | ― | 1.66% | 21.95% | |
56 Neutral | $14.76B | 136.07 | -8.96% | 2.78% | -20.17% | -138.32% | |
46 Neutral | C$201.68M | -3.28 | -23.14% | 1.87% | 20.75% | -0.36% |
On July 13, 2025, Becton, Dickinson and Company announced a Reverse Morris Trust transaction with Waters Corporation, combining its Biosciences and Diagnostic Solutions business with Waters. This strategic move will result in BD receiving approximately $4 billion in cash and its shareholders owning 39.2% of Waters’ common stock. The transaction involves several steps, including the separation of BD’s Biosciences and Diagnostic Solutions Business into a new entity, SpinCo, which will then merge with a subsidiary of Waters. This merger has been approved by both companies’ boards and is expected to enhance BD’s financial position and market influence.
The most recent analyst rating on (BDX) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.
On July 14, 2025, Becton Dickinson and Waters Corporation announced a definitive agreement to combine BD’s Biosciences and Diagnostic Solutions business with Waters in a Reverse Morris Trust transaction valued at approximately $17.5 billion. This strategic move aims to create a leading life science and diagnostics company with a strong presence in high-growth markets, doubling Waters’ total addressable market to $40 billion. The combined company is expected to generate significant shareholder value through cost and revenue synergies, with anticipated annualized EBITDA synergies of $345 million by 2030. The transaction is expected to be accretive to adjusted EPS in the first year, with a promising financial outlook projecting mid-to-high single-digit revenue growth and mid-teens adjusted EPS growth over the next five years.
The most recent analyst rating on (BDX) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.
Becton, Dickinson and Company (BD) is involved in a legal matter concerning stockholder derivative actions. A proposed settlement has been reached in the consolidated stockholder derivative litigation against BD and certain of its officers and directors, which alleges breaches of fiduciary duties and other misconduct related to the Alaris infusion pump system. The settlement, if approved by the court, will resolve the litigation and prevent further claims related to the issues. A settlement hearing is scheduled for August 11, 2025, to determine the fairness of the settlement terms.
The most recent analyst rating on (BDX) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.